Proteinuria News and Research

RSS
Proteinuria, also sometimes referred to as albuminuria or urine albumin, is a health condition characterized by an abnormal concentration of protein in the urine.
Genetic profiling ‘feasible’ for paediatric cancer patients

Genetic profiling ‘feasible’ for paediatric cancer patients

Simple blood test could help predict emergence of pre-eclampsia in pregnant women

Simple blood test could help predict emergence of pre-eclampsia in pregnant women

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

Variant signs worldwide exclusive license and development agreement with L&F Research

Variant signs worldwide exclusive license and development agreement with L&F Research

EKF biomarker identifies likely development  of Diabetic Nephropathy

EKF biomarker identifies likely development of Diabetic Nephropathy

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

Circulating protein predicts risk of chronic kidney disease

Circulating protein predicts risk of chronic kidney disease

Preeclampsia during pregnancy linked to heart defects in infants

Preeclampsia during pregnancy linked to heart defects in infants

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Sun Biomedical begins DMX-200 Phase II trial for treatment of chronic kidney disease

Sun Biomedical begins DMX-200 Phase II trial for treatment of chronic kidney disease

Study finds that serum biomarkers can predict pre-eclampsia risk in pregnant women

Study finds that serum biomarkers can predict pre-eclampsia risk in pregnant women

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

First-line axitinib ‘feasible’ in advanced, metastatic RCC

First-line axitinib ‘feasible’ in advanced, metastatic RCC

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC